TQB2450 with or without anlotinib as maintenance treatment in subjects with locally advanced/unresectable non-small cell lung cancer that have not progressed after prior concurrent/sequential chemoradiotherapy (R-ALPS): study protocol for a randomized, double-blind, placebo-controlled, multicenter phase III trial

• Published in: Translational lung cancer research Vol. 13; no. 10; pp. 2828 - 2837
• Main Authors: Dong, Baiqiang, Chen, Long, Pang, Qingsong, Jiang, Ou, Ge, Hong, Cheng, Yufeng, Zhou, Rongrong, Meng, Xiangjiao, Li, Jie, Zhu, Xuan, Wang, Xunqiang, Cao, Qiuyue, Ji, Yongling, Chen, Ming
• Format: Journal Article
• Language: English
• Published: China AME Publishing Company 31.10.2024
• Subjects: Study Protocol; maintenance therapy; anlotinib; non-small cell lung cancer (NSCLC); survival; TQB2450

Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of non-small cell lung cancer (NSCLC). TQB2450 (benmelstobart) is a novel humanized immunoglobulin G1 monoclonal antibody against programmed death-ligand 1 (PD-L1). Anlotinib, an oral multitargeted anti-angiogenic agent with poten...